RDIF, Panacea Biotec start Sputnik V Covid vaccine production starts in India

UPDATED: May 25, 2021 05:10 IST
Sputnik V was given emergency use authorisation by the Indian government on April 12 this year. (Photo: Reuters)
The Russian Direct Investment Fund (RDIF) has started the production of 'Sputnik V' Covid-19 vaccine in India in collaboration with domestic pharma major Panacea Biotec. The joint venture is going to produce 100 million doses per year of Sputnik V in India and is expected to undergo full-scale production this summer, a joint statement issued on Monday said.
RDIF, a Russian sovereign wealth fund that markets the vaccine internationally, in April had announced a collaboration with Panacea Biotec. The first batch of the vaccine will be produced at Panacea Biotec's facilities at Baddi in Himachal Pradesh. This batch will then be shipped to Russia's Gamaleya Center for "quality control", the joint statement said.

Related Keywords

Hyderabad ,Andhra Pradesh ,India ,Himachal Pradesh ,Russia ,Russian ,Bharat ,Oxford Astrazeneca ,Kirill Dmitriev ,Rajesh Jain ,Serum Institute Of India Covishield ,Russia Gamaleya Center ,Russian Direct Investment Fund ,Panacea Biotec ,Gamaleya Center ,Bharat Biotech ,Serum Institute ,Sputnik V ,Sputnikv Vaccine In India ,Sputnikv India Production ,Sputnikv Vaccine Efficacy ,Putnikv Dose India Price ,India Covid 19 News ,ஹைதராபாத் ,ஆந்திரா பிரதேஷ் ,இந்தியா ,இமாச்சல் பிரதேஷ் ,ரஷ்யா ,ரஷ்ய ,பாரத் ,ராஜேஷ் ஜெயின் ,ரஷ்ய நேரடி முதலீடு நிதி ,சஞ்சீவி பயோடெக் ,பாரத் பயோடெக் ,சீரம் நிறுவனம் ,ஸ்பட்நிக் வ் ,